S&P 500
5.048,42 -23,21 (-0,46%) Nasdaq
15.611,76 -100,99 (-0,64%) NIKKEI 225
38.038,96 +410,48 (+1,09%) Dólar/Euro
1,0730 -0,0003 (-0,03%) Petróleo Brent
89,50 +0,49 (+0,55%) Bitcoin EUR
59.989,17 +46,90 (+0,08%)
Bellerophon Therapeutics, Inc. (BLPH)
Bellerophon Therapeutics, Inc.
20 Independence Boulevard
Suite 402
Warren, NJ 07059
United States
908 574 4770
https://bellerophon.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 18
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Craig R. Jalbert CIRA | President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director | N/A | N/A | 1962 |
Descripción
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Gobierno corporativo
El ISS Governance QualityScore de Bellerophon Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
